Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

Cancer Medicine

卷:9

Tingting Sang¹  Jiang Cao¹  Linyan Xu¹  Lingyu Zeng¹  Ming Shi²  Junnian Zheng²  Meixue Yao³  Bing Zhang⁴  Cai Sun⁴  Jingjing Yang⁴  Kailin Xu⁴  Xiang Gao⁴  Hai Cheng⁴  Ying Wang⁴  Zhenyu Li⁴  Kemeng Sun⁴  Haiying Sun⁴  Dongmei Yan⁴  Jun Jiao⁴  Feng Zhu⁴  Yuanyuan Qin⁴  Xuguang Song⁴  Depeng Li⁴  Wei Sang⁴  Zhiling Yan⁴  Yuanyuan Ma⁵  Mei Wu⁵  Hui Liu⁵  Weidong Li⁶ 

[1] Blood Diseases Institute Xuzhou Medical University Xuzhou China;

[2] Cancer Institute Xuzhou Medical University Xuzhou China;

[3] Department of Epidemiology and Biostatistics School of Public Health Xuzhou Medical University Xuzhou China;

[4] Department of Hematology the Affiliated Hospital of Xuzhou Medical University Xuzhou China;

[5] Department of Pathology the Affiliated Hospital of Xuzhou Medical University Xuzhou China;

[6] Department of Radiology the Affiliated Hospital of Xuzhou Medical University Xuzhou China;

关键词: CAR‐T;    CD19;    CD20;    clinical trial;    DLBCL;   

DOI  :  10.1002/cam4.3259

来源: DOAJ

【 摘 要 】

Abstract Purpose Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coadministration of anti‐CD19 and anti‐CD20 CAR‐T cells treatment for R/R DLBCL and evaluated its efficacy and toxicity. Methods Totally 21 patients with DLBCL were enrolled in this study. The patients were conditioned with fludarabine and cyclophosphamide before the infusion of anti‐CD19 and anti‐CD20 CAR‐T cells. Treatment response, toxicity, and persistence were monitored continuously. Results Of the 21 patients received the treatment, the objective response rate (ORR) is 81.0% (95% confidence interval [CI], 58.1%‐94.6%) with four cases of bulk (4/5) and one case of testis involvement; 52.4% (95% CI, 29.8%‐74.3%) had a complete response (CR). Peak levels of anti‐CD19 and anti‐CD20 CAR cells were associated with response (P = .007 and .002). Grade 3‐4 cytokine release syndrome (CRS) and neurologic events occurred in 28.5% and 9.5% patients, respectively. Median overall survival (OS) and progression‐free survival (PFS) were 8.1 and 5.0 months, respectively. The maximum standard uptake value (SUVmax) of CD4/CD8 ratio before and after infusion were associated with responses, and the total lesion glycolysis (TLG) before infusion correlates with cytokines level. Conclusions Coadministration of anti‐CD19 and CD20 CAR‐T cells therapy for DLBCL is feasible with manageable toxicity. Cytokine markers are related to toxicity and SUVmax could predict efficacy. This trial was registered at www.clinicaltrials.gov as NCT03207178.

【 授权许可】

Unknown